Indian Journal of Cancer Home 

REVIEW ARTICLE
[View FULLTEXT] [Download PDF]
Year : 2017  |  Volume : 54  |  Issue : 5  |  Page : 1--8

Oncogenic drivers in nonsmall cell lung cancer and resistance to epidermal growth factor receptor tyrosine kinase inhibitors

A Pathak1, S Rajappa2, A Gore3 
1 Department of Oncology, Cancer Care Clinic and Hospital, Nagpur, India
2 Indo-American Cancer Institute and Research Centre, Hyderabad, Telangana, India
3 Department of Medical Oncology, Prince Aly Khan Hospital, Mumbai, Maharashtra, India

Correspondence Address:
Dr. A Pathak
Department of Oncology, Cancer Care Clinic and Hospital, Nagpur
India

Nonsmall cell lung cancer (NSCLC) is increasingly being treated with targeted therapies. Epidermal growth factor receptor (EGFR) has been extensively studied in NSCLC as an oncogenic driver. However, the efficacy of the EGFR tyrosine kinase inhibitors (TKIs) is adversely impacted by the development of resistance. The occurrence of de novo resistance to EGFR TKIs is attributed to multiple mechanisms such as point mutations of oncogenes and chromosomal rearrangements. The development of acquired resistance to EGFR TKIs is facilitated by secondary mutations, phenotypical transformation, aberrance of downstream pathways, and activation of alternate signaling pathways. The T790M mutation is the most common mutation that accounts for about half of the acquired resistance to EGFR TKIs. This review article provides an overview of the common oncogenic drivers, targeted therapies for NSCLC, and the established mechanisms implicated in the development of resistance to the EGFR TKIs.


How to cite this article:
Pathak A, Rajappa S, Gore A. Oncogenic drivers in nonsmall cell lung cancer and resistance to epidermal growth factor receptor tyrosine kinase inhibitors.Indian J Cancer 2017;54:1-8


How to cite this URL:
Pathak A, Rajappa S, Gore A. Oncogenic drivers in nonsmall cell lung cancer and resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Indian J Cancer [serial online] 2017 [cited 2018 Jan 21 ];54:1-8
Available from: http://www.indianjcancer.com/article.asp?issn=0019-509X;year=2017;volume=54;issue=5;spage=1;epage=8;aulast=Pathak;type=0